X

Trial Profile

A Phase I, Multicenter,Open-label,Dose-Escalation and Expansion Study of CS1001 in Combination With Donafenib in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donafenib (Primary) ; Sugemalimab (Primary)
Indications Carcinoma; Endometrial cancer; Head and neck cancer; Liver cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
28 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
12 Jul 2021 Planned number of patients changed from 120 to 30.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com